Geron (GERN) Stock Forecast & Price Target

$3.49 -0.17 (-4.64%)

(As of 12/20/2024 05:40 PM ET)

Geron - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
1

Buy
10

Based on 11 Wall Street analysts who have issued ratings for Geron in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for GERN.

Consensus Price Target

$7.15
104.87% Upside

According to the 11 analysts' twelve-month price targets for Geron, the average price target is $7.15. The highest price target for GERN is $10.00, while the lowest price target for GERN is $4.50. The average price target represents a forecasted upside of 104.87% from the current price of $3.49.

Get the Latest News and Ratings for GERN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Geron and its competitors.

GERN Analyst Ratings Over Time

Type	Current Forecast 12/24/23 to 12/23/24	1 Month Ago 11/24/23 to 11/23/24	3 Months Ago 9/25/23 to 9/24/24	1 Year Ago 12/24/22 to 12/24/23
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.15	$7.05	$7.06	$4.75
Forecasted Upside	104.87% Upside	73.22% Upside	53.53% Upside	107.42% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

GERN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GERN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Geron Stock vs. The Competition

Type	Geron	Medical Companies	S&P 500
Consensus Rating Score	3.09	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	104.87% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent GERN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00	+53.06%
12/10/2024	HC Wainwright 2 of 5 stars	E. Bodnar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00	+126.13%
11/29/2024	Barclays 3 of 5 stars	P. Lawson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/16/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$6.00	+43.20%
9/9/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Khurshid Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$7.00	+64.71%
Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad) You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss. Click Here to get the full details about Crypto’s Hidden Gem
8/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$8.00	+73.91%
6/10/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$6.00 ➝ $7.00	+48.94%
4/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$4.50	+8.70%
4/29/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$10.00	+163.85%
3/15/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$4.00 ➝ $5.00	+60.00%
1/9/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Patel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$4.00 ➝ $5.00	+100.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:18 AM ET.

GERN Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Geron is $7.15, with a high forecast of $10.00 and a low forecast of $4.50.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There is currently 1 hold rating, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GERN shares.
: According to analysts, Geron's stock has a predicted upside of 104.87% based on their 12-month stock forecasts.
: Over the previous 90 days, Geron's stock had 1 upgrade by analysts.
: Geron has been rated by research analysts at Barclays, HC Wainwright, Needham & Company LLC, and Scotiabank in the past 90 days.
: Analysts like Geron more than other "medical" companies. The consensus rating for Geron is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GERN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

This page (NASDAQ:GERN) was last updated on 12/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Stock Forecast & Price Target